Skip to main content
SpringerLink
Log in

Cetuximab oder Bevacizumab in der Erstlinientherapie des metastasierten kolorektalen Karzinoms?

Cetuximab or bevacizumab as first line therapy of metastasized colorectal cancer?

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Heinemann V, Weikersthal LF von, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075

    Article  CAS  PubMed  Google Scholar 

  2. Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25(Suppl 3):iii1–iii9

    Article  Google Scholar 

  3. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Article  CAS  PubMed  Google Scholar 

  4. Stintzing S, Modest DP, Fischer von Weikersthal L et al (2014) Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol 25(suppl 5):LBA10

    Google Scholar 

  5. Grothey A, Hedrick EE, Mass RD et al (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183–189

    Article  CAS  PubMed  Google Scholar 

  6. Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247

    Article  CAS  PubMed  Google Scholar 

  7. Venook A, Niedzwiecki D, Lenz H-J et al (2014) CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s (suppl; abstr LBA3)

    Article  Google Scholar 

  8. Lenz H-J, Niedzwiecki D, Innocenti F et al (2014) CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): expanded ras analyses. Ann Oncol 25(Suppl 2):Abstr 501O

    Google Scholar 

  9. Sclafani F, Cunningham D (2014) Cetuximab or bevacizumab in metastatic colorectal cancer? Lancet Oncol 15:1040–1041

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. U.T. Hacker gibt an, dass kein Interessenkonflikt besteht. Der Beitrag enthält keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Universitätsklinikum Leipzig, Universitäres Krebszentrum Leipzig (UCCL), Liebigstraße 20, 04103, Leipzig, Deutschland

    U.T. Hacker

Authors
  1. U.T. Hacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U.T. Hacker.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hacker, U. Cetuximab oder Bevacizumab in der Erstlinientherapie des metastasierten kolorektalen Karzinoms?. Onkologe 21, 160–161 (2015). https://doi.org/10.1007/s00761-014-2850-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-014-2850-8

Search

Navigation